About: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
Creator	Bozorgmehr, Farastuk Brückner, Lena Christopoulos, Petros Krisam, Johannes Mueller, Daniel Rieken, Stefan Schneider, Marc Thomas, Michael
source	Medline; PMC
abstract	BACKGROUND: Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail patients, who are frequently not capable of receiving standard therapy regimens. Despite comprising the majority of lung cancer patients, this group is underrepresented in clinical trials. This applies also to elderly and frail patients suffering from unresectable stage III NSCLC, who are unfit for chemotherapy, and, therefore, cannot receive the standard therapy comprising of radiochemotherapy and the recently approved subsequent durvalumab consolidation therapy. These patients often receive radiotherapy only, which raises the concern of undertreatment. The TRADE-hypo trial aims at optimizing treatment of this patient group by combining radiotherapy with concomitant durvalumab administration, thereby employing the immune-promoting effects of radiotherapy, and determining safety, feasibility, and efficacy of this treatment. METHODS/ DESIGN: In this prospective phase II clinical trial, durvalumab therapy will be combined with either conventionally fractionated (CON-group) or hypofractionated (HYPO-group) thoracic radiotherapy. A safety stop-and-go lead-in phase will assess safety of hypofractionated radiotherapy with respect to severe pneumonitis in small patient cohorts before opening full enrollment. Tumor tissue, blood and stool samples will be collected before and during the study period to investigate the immunological mechanisms responsible for checkpoint inhibitor efficacy and immune-promoting effects of radiotherapy. DISCUSSION: Preclinical data suggests that irradiation-induced immunogenicity can be further increased if applied in a hypofractionated setting, potentially boosting the expected synergistic effect with immune checkpoint inhibition in restoring the immune anti-tumor response. If proven safe and efficient, a hypofractionated radiation schedule can provide a considerably more practicable option for the patient. Taking into consideration the intend to develop a combination treatment strategy that can be made available to patients soon after proving to be efficient and the potentially elevated toxicity of a hypofractionated radiotherapy approach, this trial was designed as a two-trials-in-one design. An accompanying translational research program is planned striving to gain insights into the tumor-host biology and to identify suitable biomarkers to predict therapy response. TRIAL REGISTRATION: Clinicaltrials.gov, NCT04351256. Registered 17 April 2020, Eudra-CT, 2019–002192-33. Registered 24 October 2019,
has issue date	2020-08-26(xsd:dateTime)
bibo:doi	10.1186/s12885-020-07264-8
bibo:pmid	32842974
has license	cc-by
sha1sum (hex)	c5b787a060736f9de450590f79c865f8957725bc
schema:url	https://doi.org/10.1186/s12885-020-07264-8
resource representing a document's title	Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
has PubMed Central identifier	PMC7447611
has PubMed identifier	32842974
schema:publication	BMC Cancer
resource representing a document's body	covid:c5b787a060736f9de450590f79c865f8957725bc#body_text
is schema:about of	named entity 'patients' named entity 'optimizing' named entity 'administration' named entity 'group' named entity 'elderly' named entity 'Non-small cell lung cancer' named entity 'durvalumab' named entity 'radiotherapy' named entity 'III' named entity 'NON-SMALL CELL LUNG CANCER' named entity 'STANDARD THERAPY' named entity 'RECENTLY' named entity 'ELDERLY' named entity 'DURVALUMAB' named entity 'TREATMENT' named entity 'PROMOTING' named entity 'UNRESECTABLE' named entity 'efficacy' named entity 'durvalumab' named entity 'therapeutic' named entity 'patients' named entity 'Despite' named entity 'durvalumab' named entity 'durvalumab' named entity 'lung cancer' named entity 'clinical trials' named entity 'stage III' named entity 'Thoracic' named entity 'stage III' named entity 'durvalumab' named entity 'radiotherapy' named entity 'radiation dose' named entity 'metastatic tumor' named entity 'alopecia' named entity 'clinical study' named entity 'interstitial lung disease' named entity 'CT image' named entity 'radiotherapy' named entity 'NSCLC' named entity '1, 2' named entity 'durvalumab' named entity 'efficacies' named entity 'treatment groups' named entity 'clinical trial' named entity 'AEs' named entity 'inclusion and exclusion criteria' named entity 'organ' named entity 'statistical assumption' named entity 'durvalumab' named entity 'cardiac arrhythmia' named entity 'eCRF' named entity 'Northwest Hospital' named entity 'antigen' named entity 'PD-L1' named entity 'downregulate' named entity 'progression-free survival' named entity 'RECIST' named entity 'chemotherapy' named entity 'Eastern Cooperative Oncology Group' named entity 'NSCLC' named entity 'NSCLC' named entity 'allogenic' named entity 'non-small cell lung cancer' named entity 'therapeutic strategies' named entity '1, 2' named entity 'SAS' named entity 'radiology' named entity 'first-line' named entity 'remission' named entity 'durvalumab' named entity 'clinical trials' named entity 'Secondary endpoints' named entity 'TRT' named entity 'gastrointestinal conditions'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software